Abiopharma

🔍 Bluestone Jeffrey (Director)

Company: GILEAD SCIENCES, INC. (GILD)

Report Date: 2026-08-20

Detailed Transactions and Holdings:

• Acquired 1,165 shares of Common Stock at $67.45 per share (Direct)
  Date: 2026-08-20 | Code: M | equity_swap_involved: 0 | shares_owned_after: 11,231.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 1,165 shares of Common Stock at $143.7543 per share (Direct)
  Date: 2026-08-20 | Code: S | equity_swap_involved: 0 | shares_owned_after: 10,066.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Acquired 1,816 shares of Common Stock at $67.45 per share (Direct)
  Date: 2026-08-20 | Code: M | equity_swap_involved: 0 | shares_owned_after: 11,882.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 1,816 shares of Common Stock at $144.9248 per share (Direct)
  Date: 2026-08-20 | Code: S | equity_swap_involved: 0 | shares_owned_after: 10,066.00 | transaction_form_type: 4 | Footnotes: F1, F3
• Acquired 1,658 shares of Common Stock at $67.45 per share (Direct)
  Date: 2026-08-20 | Code: M | equity_swap_involved: 0 | shares_owned_after: 11,724.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 1,658 shares of Common Stock at $145.7286 per share (Direct)
  Date: 2026-08-20 | Code: S | equity_swap_involved: 0 | shares_owned_after: 10,066.00 | transaction_form_type: 4 | Footnotes: F1, F4
• Acquired 26 shares of Common Stock at $67.45 per share (Direct)
  Date: 2026-08-20 | Code: M | equity_swap_involved: 0 | shares_owned_after: 10,092.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 26 shares of Common Stock at $146.36 per share (Direct)
  Date: 2026-08-20 | Code: S | equity_swap_involved: 0 | shares_owned_after: 10,066.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 335 shares of Common Stock at $61.35 per share (Direct)
  Date: 2026-08-20 | Code: M | equity_swap_involved: 0 | shares_owned_after: 10,401.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 335 shares of Common Stock at $146.26 per share (Direct)
  Date: 2026-08-20 | Code: S | equity_swap_involved: 0 | shares_owned_after: 10,066.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 4,665 shares of Non-qualified Stock Option (Right to Buy) at $67.45 per share (Derivative)
  Date: 2026-08-20 | Code: M | Expires: 2031-05-12 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1, F5
• Sold 335 shares of Non-qualified Stock Option (Right to Buy) at $61.35 per share (Derivative)
  Date: 2026-08-20 | Code: M | Expires: 2032-05-05 | equity_swap_involved: 0 | shares_owned_after: 11,395.00 | transaction_form_type: 4 | Footnotes: F1, F6

Footnotes:

• F1: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on May 20, 2026.
• F2: Sale prices for the transactions reported range from $143.31 to $144.16. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.
• F3: Sale prices for the transactions reported range from $144.32 to $145.31. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.
• F4: Sale prices for the transactions reported range from $145.34 to $146.23. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.
• F5: 25% of the shares subject to the option vested on each three-month anniversary from May 12, 2021 such that 100% of the shares subject to the option are fully vested.
• F6: 100% of the shares subject to the stock option vested immediately upon the grant date of May 5, 2022.